ESR1 and breast cancer: To evaluate the working hypothesis that the Y1R is a potential diagnostic target in breast cancer, we performed preclinical investigations on ER and NPY receptor expression and function, taking into account the impact of standard therapies using antiestrogens or aromatase inhibitors.